Faron Pharmaceuticals Oy Director/PDMR Shareholding (0993B)
18 September 2018 - 6:23PM
UK Regulatory
TIDMFARN
RNS Number : 0993B
Faron Pharmaceuticals Oy
18 September 2018
Faron Pharmaceuticals Oy
("Faron" or the "Company")
Person Closely Associated with PDMR Dealing
TURKU - FINLAND, 18 September 2018 - Faron Pharmaceuticals Ltd
("Faron") (LON: FARN), the clinical stage biopharmaceutical
company, announces that on 17 September 2018 it was notified of the
following person closely associated with PDMR dealing.
On 17 September 2018, a person closely associated with Dr. Matti
Karvonen, Chief Medical Officer of Faron, had acquired 4,414
ordinary shares in Faron at a price of 100 pence per ordinary
share.
The notification below, which has been made in accordance with
the requirements of the EU Market Abuse Regulation, provides
further detail.
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) No 596/2014 ("MAR").
Notification of a Transaction pursuant to Article 19(1) of Regulation
(EU) No. 596/2014
1 Details of the person discharging managerial responsibilities/person
closely associated
---- ------------------------------------------------------------------------------------
a. Name
Minja Pfeiffer
-------------------------------------------------------
2 Reason for notification
--------------------------- -------------------------------------------------------
a. Position/Status A person closely associated with the Chief
Medical Officer
--------------------------- -------------------------------------------------------
b. Initial notification/ Initial Notification
Amendment
--------------------------- -------------------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
------------------------------------------------------------------------------------
a. Name Faron Pharmaceuticals Oy
---------------------------
b. LEI 7437009H31TO1DC0EB42
--------------------------- -------------------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
---- ------------------------------------------------------------------------------------
a. Description of Ordinary shares
the financial
instrument, type ISIN: FI4000153309
of instrument
Identification
Code
--------------------------- -------------------------------------------------------
b. Nature of the Purchase of ordinary shares
transaction
--------------------------- -------------------------------------------------------
c. Price(s) and volume(s) Price(s) Volume(s)
--------------------------- ------------
100 pence 4,414
-------------------------------------------------- -----------
d. Aggregated information
- Aggregated Volume N/A
- Price N/A
--------------------------- -------------------------------------------------------
e. Date of the transaction September 17, 2018
--------------------------- -------------------------------------------------------
f. Place of the transaction London Stock Exchange, AIM Market
--------------------------- -------------------------------------------------------
For more information please contact:
Faron Pharmaceuticals Ltd
Dr Markku Jalkanen, Chief Executive Officer
investor.relations@faron.com
Consilium Strategic Communications
Mary-Jane Elliott, David Daley, Matthew Neal, Lindsey
Neville
Phone: +44 (0)20 3709 5700
E-mail: faron@consilium-comms.com
Westwicke Partners, IR (US)
Chris Brinzey
Phone: 01 339 970 2843
E-Mail: chris.brinzey@westwicke.com
Panmure Gordon (UK) Limited, Nomad and Broker
Freddy Crossley, Emma Earl
Phone: +44 207 886 2500
About Faron Pharmaceuticals Ltd
Faron (AIM:FARN) is a clinical stage biopharmaceutical company
developing novel treatments for medical conditions with significant
unmet needs. The Company currently has a pipeline focusing on acute
organ traumas, vascular damage and cancer immunotherapy. The
Company's lead candidate Traumakine, to prevent vascular leakage
and organ failures, is currently the only treatment for Acute
Respiratory Distress Syndrome (ARDS) undergoing Phase III clinical
trials and in 2017 received advice from US FDA to proceed directly
to BLA submission following completion of EU and Japanese Phase III
studies. There is currently no approved pharmaceutical treatment
for ARDS. An additional European Phase II Traumakine trial is
underway for the Rupture of Abdominal Aorta Aneurysm ("RAAA").
Faron's second candidate Clevegen is a ground breaking pre-clinical
anti-Clever-1 antibody. Clevegen has the ability to switch immune
suppression to immune activation in various conditions, with
potential across oncology, infectious disease and vaccine
development. This novel macrophage-directed immuno-oncology switch
called Turn-on-your-Immunity or Turn-It may be used alone or in
combination with other immune checkpoint molecules for the
treatment of cancer patients. Faron is based in Turku, Finland.
Further information is available at www.faron.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHFKFDBFBKKBCD
(END) Dow Jones Newswires
September 18, 2018 04:23 ET (08:23 GMT)
Faron Pharmaceuticals Oy (LSE:FARN)
Historical Stock Chart
From Apr 2024 to May 2024
Faron Pharmaceuticals Oy (LSE:FARN)
Historical Stock Chart
From May 2023 to May 2024